Dalal Street Hot Chips Buy Calls – Parenteral Drugs India
PARENTERAL DRUGS
BSE Code: 524689
Volume: 230000
CMP: Rs 245.85
Parenteral Drugs India (PDIL) has recently set up a critical care division to market its product basket, including the Paracetamol-based IV fluid. PDIL targets peak revenues of Rs 150 crore from this in the next two years led by higher volumes and margins, high-end IV fluids like fat emulsions, aminoacids etc and anesthesia under as fundamentals may Piramal Healthcare. Besides, it has also strategically diversified into oncology, UNOPS (United Nations Offices for Project Services) supply, etc. PDIL aims to treble its revenues from its oncology business in FY11E, led by robust sales in international markets. PDIL also aims at revenues of at least Rs 70 crore from its UNOPS’ orders in FY11E. The company is also expanding its geographical reach beyond the domestic borders through its international JVs in Mauritius, Kenya, Kazakhstan etc. The stock can be looked at for short to medium-term gain
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
I am impressed.